DILATED CARDIOMYOPATHY

✓ Medically ReviewedDISEASEID: MDBT0160🚨 TRIAGE: URGENTICD-10: I42.0

📖

Definition

CLINICAL DEFINITION

Dilated cardiomyopathy (DCM) is a primary myocardial disease characterised by progressive dilation of the left ventricle or both ventricles, accompanied by systolic dysfunction, in the absence of abnormal loading conditions (e.g., severe hypertension, valvular disease) or coronary artery disease sufficient to cause global systolic impairment.

IN PLAIN ENGLISH

Dilated cardiomyopathy is a condition where the heart muscle becomes weakened and the main pumping chamber stretches and enlarges. Because the heart is enlarged and weak, it cannot pump blood efficiently to the rest of the body, which can lead to heart failure.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Dilated cardiomyopathy is NOT heart failure itself, though it is a leading cause of it; heart failure is the clinical syndrome resulting from the impaired pumping. It is also NOT ischaemic cardiomyopathy, where the dilation and dysfunction are primarily caused by blocked coronary arteries and previous heart attacks.

🔤

Word Breakdown

cardio-

=heart (from Greek 'kardia')

-myopathy

=muscle disease (from Greek 'mys' for muscle and 'pathos' for disease)

Literal Meaning: Disease of the heart muscle characterised by dilation

🏷️

Abbreviations

DCM=Dilated Cardiomyopathy — primary clinical abbreviation for the disease

HFrEF=Heart Failure with reduced Ejection Fraction — the typical haemodynamic consequence of DCM

LVEF=Left Ventricular Ejection Fraction — key measurement for diagnosis and monitoring

🔄

Synonyms & Variants

Congestive Cardiomyopathy›Idiopathic Dilated Cardiomyopathy›

🎯

Category-Specific Context

As a Disease, dilated cardiomyopathy represents a specific structural and functional pathological state of the myocardium. It is classified within the broader spectrum of cardiomyopathies (dilated, hypertrophic, restrictive, arrhythmogenic, and unclassified) and is a primary structural cause of heart failure with reduced ejection fraction (HFrEF).

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Cardiology Outpatient ClinicHeart Failure UnitEmergency DepartmentCardiac Intensive Care UnitGeneral Medicine Ward

USAGE & DOCUMENTATION NOTES

In clinical documentation, DCM is often documented alongside the left ventricular ejection fraction (LVEF), e.g., 'DCM with LVEF 25%'. It is frequently coded or referred to under the umbrella of 'HFrEF' (Heart Failure with reduced Ejection Fraction) in heart failure pathways. Notes often specify the suspected aetiology, such as 'familial DCM', 'alcoholic DCM', or 'idiopathic DCM', and document the presence or absence of device therapy (ICD/CRT).

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

The pathophysiology of DCM involves initial myocardial injury from genetic mutations, toxins, infections, or autoimmune processes, leading to cardiomyocyte loss and dysfunction. To maintain stroke volume, the left ventricle undergoes eccentric remodelling, characterised by chamber dilation and wall thinning according to the Law of Laplace. This increases wall stress and myocardial oxygen demand, further promoting cardiomyocyte apoptosis and interstitial fibrosis. Neurohormonal activation, including the renin-angiotensin-aldosterone and sympathetic nervous systems, initially compensates but eventually drives progressive maladaptive remodelling, worsening systolic dysfunction, and ultimately culminating in the clinical syndrome of heart failure and an increased risk of malignant ventricular arrhythmias.

PRIMARY CAUSES

Genetic/Familial mutations

Mutations in genes encoding cytoskeletal, sarcomeric, or nuclear envelope proteins (e.g., TTN, LMNA, MYH7) disrupt cardiomyocyte structural integrity and force transmission.

Viral myocarditis

Direct viral cytotoxicity (e.g., Coxsackievirus, Parvovirus B19) and subsequent autoimmune inflammation lead to cardiomyocyte necrosis and replacement fibrosis.

Toxic exposure (Alcohol)

Chronic excessive alcohol consumption and its metabolites cause direct toxic damage to myocardial mitochondria and impair protein synthesis.

Chemotherapy agents (Anthracyclines)

Doxorubicin and related drugs generate reactive oxygen species and inhibit topoisomerase-II-beta, causing cumulative, dose-dependent cardiomyocyte death.

Peripartum cardiomyopathy

Late-pregnancy or postpartum oxidative stress and anti-angiogenic factors (e.g., soluble fms-like tyrosine kinase-1) induce myocardial damage in susceptible individuals.

Idiopathic

No identifiable genetic, infectious, or toxic cause is found despite comprehensive evaluation; likely represents unrecognised prior viral or immune-mediated injury.

💊

Drug-Induced Causes

💊 Anthracyclines (doxorubicin, epirubicin) ↗

Mechanism: Generation of free radicals and topoisomerase-II-beta inhibition causing dose-dependent cardiomyocyte apoptosis.

→ Discontinue offending agent. Initiate guideline-directed HFrEF therapy. Consider dexrazoxane for prophylaxis in high-risk oncology patients.

💊 Targeted cancer therapies (trastuzumab) ↗

Mechanism: Blockade of HER2/neu signalling pathways critical for cardiomyocyte survival and repair, often exacerbated by concurrent anthracyclines.

→ Withhold trastuzumab if LVEF drops significantly. Initiate ACE inhibitors and beta-blockers; function is often reversible upon discontinuation.

💊 Alcohol (chronic heavy use) ↗

Mechanism: Direct toxic effect of ethanol and acetaldehyde on myocardial mitochondria and contractile proteins.

→ Absolute abstinence from alcohol is required, which can lead to significant recovery of ventricular function in early stages.

🌍

Epidemiology

Prevalence:The estimated prevalence of DCM is approximately 1 in 250 to 1 in 500 individuals in the general population, making it the most common cardiomyopathy and a leading indication for heart transplantation.

Age Group:Can present at any age, but most commonly diagnosed in adults aged 20 to 60 years. Genetic forms may present in childhood or young adulthood, while toxic or ischaemic forms typically present in middle to older age.

Sex Predilection:Male

Geographic Distribution:Globally distributed. Chagas disease (caused by Trypanosoma cruzi) is a leading infectious cause of secondary DCM in endemic regions of Latin America. Alcoholic DCM prevalence correlates with regional patterns of heavy alcohol consumption.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

New-onset heart failure with a history of heavy alcohol use or recent viral illness — consider toxic or inflammatory aetiologies which may be partially or fully reversible with abstinence or immunosuppression.
DCM with conduction system disease (e.g., AV block) or atrial arrhythmias — raises high suspicion for a lamin A/C (LMNA) gene mutation, which carries a high risk of sudden cardiac death and requires early consideration of an ICD regardless of LVEF.

URGENT EVALUATION TRIGGERS

Syncope or presyncope — requires urgent evaluation for malignant ventricular arrhythmias or high-degree AV block.
Acute dyspnoea at rest, orthopnoea, or pink frothy sputum — indicates acute decompensated heart failure requiring immediate diuresis and respiratory support.
New-onset chest pain or palpitations with haemodynamic instability — requires urgent ECG and troponin to rule out acute coronary syndrome or sustained ventricular tachycardia.

Contraindications & Precautions

CONTRAINDICATIONS

Non-dihydropyridine calcium channel blockers (verapamil
diltiazem) — contraindicated in HFrEF due to negative inotropic effects that can precipitate cardiogenic shock.
Most antiarrhythmics (e.g.
flecainide
propafenone) — contraindicated due to pro-arrhythmic risk and negative inotropy in structural heart disease.
NSAIDs and COX-2 inhibitors — generally avoided as they promote sodium and water retention
worsening heart failure and antagonising diuretics.

SPECIAL PRECAUTIONS

Beta-blockers must be initiated at low doses and titrated slowly only when the patient is euvolaemic and haemodynamically stable
as they can acutely worsen decompensated heart failure.
Pregnancy requires careful pre-conception counselling and medication adjustment
as some GDMT drugs (e.g.
ACE inhibitors
ARBs
ARNIs) are teratogenic.
Implantable cardioverter-defibrillator (ICD) placement is generally deferred until after at least 3 months of optimal GDMT
as reverse remodelling may improve LVEF above the primary prevention threshold.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Heart failure — progressive decline in cardiac output leading to systemic and pulmonary congestion.
Malignant ventricular arrhythmias — structural remodelling and fibrosis create re-entrant circuits
increasing the risk of ventricular tachycardia and sudden cardiac death.
Thromboembolism — blood stasis in the dilated
poorly contracting ventricle and atrial fibrillation increase the risk of mural thrombus formation and systemic emboli (e.g.
stroke).
Functional mitral/tricuspid regurgitation — annular dilation secondary to ventricular enlargement prevents proper leaflet coaptation.

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Hypertrophic Cardiomyopathy

Shares the 'cardiomyopathy' suffix but represents a distinct disease characterised by thickened ventricular walls and preserved or hyperdynamic systolic function, unlike the dilated, weak ventricles of DCM.

Ischaemic Cardiomyopathy

Often presents with identical clinical heart failure and dilation, but the primary aetiology is severe coronary artery disease rather than primary myocardial disease.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Ischaemic Cardiomyopathy

Key Distinguishing Feature: History of myocardial infarction, significant coronary artery disease on angiography, or regional wall motion abnormalities corresponding to a vascular territory.

Hypertensive Heart Disease

Key Distinguishing Feature: Long-standing, poorly controlled severe hypertension leading to left ventricular hypertrophy before eventual dilation; usually accompanied by a thickened LV wall initially.

Valvular Heart Disease (e.g., severe aortic regurgitation)

Key Distinguishing Feature: Volume overload from a primary valvular defect causes secondary ventricular dilation; echocardiography identifies the primary structural valve abnormality.

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Key Distinguishing Feature: Primarily affects the right ventricle with fibrofatty replacement, presenting with right-sided heart failure and specific ECG changes (e.g., epsilon waves), though LV involvement can occur late.

💎

Clinical Pearls

💎

Always exclude ischaemic heart disease (via stress testing or coronary angiography) in adults presenting with new-onset DCM, as revascularisation can reverse ischaemic cardiomyopathy.

💎

Tachycardia-induced cardiomyopathy is a fully reversible cause of DCM; strict rate or rhythm control of chronic atrial fibrillation or other tachyarrhythmias can normalise LVEF over months.

💎

Family screening is mandatory for idiopathic DCM. First-degree relatives should undergo clinical evaluation and echocardiography, and genetic counselling should be offered if a pathogenic mutation is identified in the proband.

💎

An ICD is indicated for primary prevention of sudden cardiac death in patients with LVEF ≤35% and NYHA class II-III symptoms despite at least 3 months of optimal GDMT, provided survival with good functional capacity is expected for >1 year.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"The patient is a 45-year-old male with newly diagnosed idiopathic dilated cardiomyopathy, presenting with NYHA class III heart failure symptoms and an LVEF of 25% on optimal medical therapy."

IN A SOAP NOTE

S: 52-year-old male presents with progressive exertional dyspnoea, orthopnoea, and bilateral lower extremity swelling over the past 3 weeks. O: BP 105/70 mmHg, HR 92 bpm irregular, RR 22, SpO2 94% on room air. JVP elevated at 8 cm. Bibasilar crackles. S3 gallop present. 2+ pitting oedema to mid-shins. ECG shows atrial fibrillation with rapid ventricular response. Echo reveals severely dilated LV with global hypokinesia and LVEF 20%. A: Acute decompensated heart failure secondary to newly diagnosed dilated cardiomyopathy. New-onset atrial fibrillation. P: Admit for IV diuresis. Initiate rate control with digoxin/amiodarone (avoiding beta-blockers acutely). Start GDMT once euvolaemic. Schedule coronary CTA to exclude ischaemic aetiology. Consult electrophysiology for AF management and consider genetic testing.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for dilated cardiomyopathy with reduced EF: (1) Ischaemic cardiomyopathy — assess via coronary angiography or CT; (2) Toxic/Metabolic — review alcohol history, chemotherapy exposure, and thyroid function; (3) Infectious/Inflammatory — consider viral serology, HIV, or Chagas in endemic areas; (4) Genetic/Familial — evaluate family history and consider targeted gene panel testing.

📊

Classifications & Scoring

GRADING SYSTEM

NYHA Functional Classification

Grades the severity of heart failure symptoms from Class I (no limitation) to Class IV (symptoms at rest). Used to guide therapy and assess prognosis in DCM.

STAGING SCALE

ACC/AHA Stages of Heart Failure

Stages heart failure from Stage A (at risk) to Stage D (refractory). DCM patients typically present in Stage B (structural heart disease without symptoms) or Stage C (structural disease with prior/current symptoms).

SCORING TOOL

Seattle Heart Failure Model

Predicts 1-, 2-, and 5-year survival in patients with heart failure using clinical, laboratory, and medication variables. Useful for timing advanced therapies in DCM.

SCORING TOOL

MAGGIC Risk Score

A widely used meta-analysis global grouping in chronic heart failure risk calculator that estimates mortality based on clinical and echocardiographic parameters.

📈

Prognosis

SHORT-TERM OUTCOME

With the initiation of optimal guideline-directed medical therapy (GDMT), many patients experience reverse remodelling and symptomatic improvement within 3 to 6 months. Acute decompensated presentations require hospitalisation but often stabilise with diuresis and intravenous therapies.

LONG-TERM PROGNOSIS

Historically poor, but modern GDMT and device therapy (ICDs, CRT) have significantly improved survival. The 5-year survival rate is now approximately 70-80% for treated patients. However, a subset progresses to end-stage refractory heart failure, requiring advanced therapies such as a left ventricular assist device (LVAD) or heart transplantation.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

I42.0

LITERATURE CITATIONS & GUIDELINES

[1]Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.

[2]Schultheiss HP et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):35.

[3]Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531-547.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.